Overview

Barrett's Esophagus - 315 - 3 Way Cross Over

Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue. All patients will have a baseline endoscopy with multiple biopsies. The patients will then be receive four dosing regimens (esomeprazole, esomeprazole and aspirin, esomeprazole and rofecoxib, or rofecoxib alone) consecutively each for a 10 day dosing period, whilst undergoing further follow up endoscopies and multiple biopsies.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Aspirin
Esomeprazole
Rofecoxib